There are 2137 resources available
273O - nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
Presenter: Erika Hamilton
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA43 - Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Presenter: Paul Nathan
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
Presenter: Ana Maria Arance Fernandez
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)
Presenter: Paolo Ascierto
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
CN26 - Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland: A qualitative study
Presenter: Sara Colomer-Lahiguera
Session: EONS13: Oncology care during Covid-19: How does it affect our patients
Resources:
Abstract
Slides
Webcast
CN29 - SARS-CoV-2 and the perspectives of people living with cancer: The AIIAO survey on the Italian lockdown
Presenter: Valentina Biagioli
Session: EONS13: Oncology care during Covid-19: How does it affect our patients
Resources:
Abstract
Webcast
LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence
Presenter: Masahiro Tsuboi
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
LBA2 - Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
Presenter: Benjamin Solomon
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
696O_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial
Presenter: Toni Choueiri
Session: Presidential Symposium I
Resources:
Abstract
Slides
Webcast
CN34 - Management of immunotherapy toxicities: A new challenge
Presenter: Laura Bascuñana Sanchez
Session: EONS13: Immunotherapy and precision oncology: What do patients need?
Resources:
Abstract
Slides
Webcast